|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: AGTRAP |
Gene summary for AGTRAP |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | AGTRAP | Gene ID | 57085 |
| Gene name | angiotensin II receptor associated protein | |
| Gene Alias | ATRAP | |
| Cytomap | 1p36.22 | |
| Gene Type | protein-coding | GO ID | GO:0001666 | UniProtAcc | Q6RW13 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57085 | AGTRAP | LZE2T | Human | Esophagus | ESCC | 1.79e-02 | 4.79e-01 | 0.082 |
| 57085 | AGTRAP | LZE4T | Human | Esophagus | ESCC | 4.72e-15 | 4.08e-01 | 0.0811 |
| 57085 | AGTRAP | LZE5T | Human | Esophagus | ESCC | 4.56e-07 | 4.79e-01 | 0.0514 |
| 57085 | AGTRAP | LZE7T | Human | Esophagus | ESCC | 1.78e-14 | 4.38e-01 | 0.0667 |
| 57085 | AGTRAP | LZE8T | Human | Esophagus | ESCC | 5.39e-03 | 2.34e-01 | 0.067 |
| 57085 | AGTRAP | LZE20T | Human | Esophagus | ESCC | 2.50e-05 | 2.78e-01 | 0.0662 |
| 57085 | AGTRAP | LZE22D1 | Human | Esophagus | HGIN | 7.63e-05 | 2.09e-01 | 0.0595 |
| 57085 | AGTRAP | LZE22T | Human | Esophagus | ESCC | 7.30e-06 | 5.02e-01 | 0.068 |
| 57085 | AGTRAP | LZE24T | Human | Esophagus | ESCC | 1.66e-33 | 1.17e+00 | 0.0596 |
| 57085 | AGTRAP | LZE22D3 | Human | Esophagus | HGIN | 1.06e-02 | 3.58e-01 | 0.0653 |
| 57085 | AGTRAP | LZE6T | Human | Esophagus | ESCC | 5.34e-20 | 1.06e+00 | 0.0845 |
| 57085 | AGTRAP | P1T-E | Human | Esophagus | ESCC | 2.85e-12 | 7.06e-01 | 0.0875 |
| 57085 | AGTRAP | P2T-E | Human | Esophagus | ESCC | 2.65e-75 | 1.48e+00 | 0.1177 |
| 57085 | AGTRAP | P4T-E | Human | Esophagus | ESCC | 3.14e-31 | 7.29e-01 | 0.1323 |
| 57085 | AGTRAP | P5T-E | Human | Esophagus | ESCC | 1.09e-53 | 1.18e+00 | 0.1327 |
| 57085 | AGTRAP | P8T-E | Human | Esophagus | ESCC | 1.65e-24 | 5.22e-01 | 0.0889 |
| 57085 | AGTRAP | P9T-E | Human | Esophagus | ESCC | 2.69e-26 | 7.51e-01 | 0.1131 |
| 57085 | AGTRAP | P10T-E | Human | Esophagus | ESCC | 4.66e-19 | 3.31e-01 | 0.116 |
| 57085 | AGTRAP | P11T-E | Human | Esophagus | ESCC | 2.05e-34 | 1.51e+00 | 0.1426 |
| 57085 | AGTRAP | P12T-E | Human | Esophagus | ESCC | 3.01e-20 | 4.14e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007048220 | Esophagus | HGIN | response to oxygen levels | 76/2587 | 347/18723 | 2.36e-05 | 6.25e-04 | 76 |
| GO:003629320 | Esophagus | HGIN | response to decreased oxygen levels | 70/2587 | 322/18723 | 6.23e-05 | 1.44e-03 | 70 |
| GO:000166620 | Esophagus | HGIN | response to hypoxia | 67/2587 | 307/18723 | 7.82e-05 | 1.75e-03 | 67 |
| GO:004343420 | Esophagus | HGIN | response to peptide hormone | 79/2587 | 414/18723 | 1.60e-03 | 1.79e-02 | 79 |
| GO:190165318 | Esophagus | HGIN | cellular response to peptide | 68/2587 | 359/18723 | 3.88e-03 | 3.54e-02 | 68 |
| GO:0070482111 | Esophagus | ESCC | response to oxygen levels | 218/8552 | 347/18723 | 6.91e-11 | 2.17e-09 | 218 |
| GO:0036293111 | Esophagus | ESCC | response to decreased oxygen levels | 201/8552 | 322/18723 | 8.37e-10 | 2.04e-08 | 201 |
| GO:0001666111 | Esophagus | ESCC | response to hypoxia | 192/8552 | 307/18723 | 1.59e-09 | 3.69e-08 | 192 |
| GO:190165319 | Esophagus | ESCC | cellular response to peptide | 208/8552 | 359/18723 | 1.68e-06 | 2.01e-05 | 208 |
| GO:0043434111 | Esophagus | ESCC | response to peptide hormone | 234/8552 | 414/18723 | 4.93e-06 | 5.21e-05 | 234 |
| GO:007137516 | Esophagus | ESCC | cellular response to peptide hormone stimulus | 166/8552 | 290/18723 | 4.48e-05 | 3.55e-04 | 166 |
| GO:004343412 | Liver | Cirrhotic | response to peptide hormone | 149/4634 | 414/18723 | 1.70e-07 | 4.49e-06 | 149 |
| GO:007137511 | Liver | Cirrhotic | cellular response to peptide hormone stimulus | 110/4634 | 290/18723 | 3.73e-07 | 8.82e-06 | 110 |
| GO:190165311 | Liver | Cirrhotic | cellular response to peptide | 129/4634 | 359/18723 | 1.23e-06 | 2.49e-05 | 129 |
| GO:00704827 | Liver | Cirrhotic | response to oxygen levels | 125/4634 | 347/18723 | 1.55e-06 | 3.02e-05 | 125 |
| GO:00362937 | Liver | Cirrhotic | response to decreased oxygen levels | 113/4634 | 322/18723 | 1.87e-05 | 2.52e-04 | 113 |
| GO:00016667 | Liver | Cirrhotic | response to hypoxia | 108/4634 | 307/18723 | 2.51e-05 | 3.26e-04 | 108 |
| GO:19043851 | Liver | Cirrhotic | cellular response to angiotensin | 14/4634 | 25/18723 | 8.15e-04 | 5.95e-03 | 14 |
| GO:19907761 | Liver | Cirrhotic | response to angiotensin | 15/4634 | 28/18723 | 9.91e-04 | 6.98e-03 | 15 |
| GO:004343422 | Liver | HCC | response to peptide hormone | 247/7958 | 414/18723 | 9.55e-13 | 4.77e-11 | 247 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| AGTRAP | SNV | Missense_Mutation | rs146377549 | c.143N>A | p.Arg48Gln | p.R48Q | Q6RW13 | protein_coding | deleterious(0.01) | possibly_damaging(0.449) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| AGTRAP | SNV | Missense_Mutation | c.415G>A | p.Ala139Thr | p.A139T | Q6RW13 | protein_coding | tolerated(0.43) | benign(0.003) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| AGTRAP | SNV | Missense_Mutation | c.154N>T | p.Asp52Tyr | p.D52Y | Q6RW13 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| AGTRAP | SNV | Missense_Mutation | rs750218314 | c.332G>A | p.Arg111Gln | p.R111Q | Q6RW13 | protein_coding | tolerated(0.13) | benign(0.072) | TCGA-BG-A0MG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| AGTRAP | SNV | Missense_Mutation | novel | c.409N>C | p.Asp137His | p.D137H | Q6RW13 | protein_coding | deleterious(0) | probably_damaging(0.989) | TCGA-DF-A2KS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| AGTRAP | SNV | Missense_Mutation | novel | c.280N>A | p.Leu94Ile | p.L94I | Q6RW13 | protein_coding | deleterious(0.01) | benign(0.37) | TCGA-EY-A215-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| AGTRAP | SNV | Missense_Mutation | novel | c.344N>T | p.Gly115Val | p.G115V | Q6RW13 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-ZP-A9CZ-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| AGTRAP | SNV | Missense_Mutation | novel | c.140N>T | p.Gln47Leu | p.Q47L | Q6RW13 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-22-1005-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| AGTRAP | SNV | Missense_Mutation | c.364N>T | p.Gly122Cys | p.G122C | Q6RW13 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-34-5240-01 | Lung | lung squamous cell carcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | CR | |
| AGTRAP | SNV | Missense_Mutation | novel | c.320A>G | p.Tyr107Cys | p.Y107C | Q6RW13 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |